Skip to main content

Arbuckle Stuart A's Form 4 filing

Vertex Pharmaceuticals Inc (VRTX) · filed Feb 16, 2023

Accession no.
0001209191-23-010050
Filed
Feb 16, 2023
Trade date
Feb 14, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 6 non-derivative transactions. Open-market sales total $1.91M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Arbuckle Stuart ACIK 0001557290Officer (EVP, COO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 14, 2023Common StockSSaleDisposed−800$295.84F2,F3−$236,67281,203Direct
Feb 14, 2023Common StockSSaleDisposed−901$296.85F2,F4−$267,461.8580,302Direct
Feb 14, 2023Common StockSSaleDisposed−560$298.14F2,F5−$166,958.479,742Direct
Feb 14, 2023Common StockSSaleDisposed−2,003$299.13F2,F6−$599,157.3977,739Direct
Feb 14, 2023Common StockSSaleDisposed−1,734$300.09F2,F7−$520,356.0676,005Direct
Feb 14, 2023Common StockSSaleDisposed−400$300.89F2,F8−$120,35675,605Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Referenced by the price of 6 transactions in Table I.

F3

Open market sales reported on this line occurred at a weighted average price of $295.84 (range $295.34 to $296.20).

Referenced by the price of 1 transaction in Table I.

F4

Open market sales reported on this line occurred at a weighted average price of $296.85 (range $296.49 to $297.30).

Referenced by the price of 1 transaction in Table I.

F5

Open market sales reported on this line occurred at a weighted average price of $298.14 (range $297.59 to $298.57).

Referenced by the price of 1 transaction in Table I.

F6

Open market sales reported on this line occurred at a weighted average price of $299.13 (range $298.68 to $299.60).

Referenced by the price of 1 transaction in Table I.

F7

Open market sales reported on this line occurred at a weighted average price of $300.09 (range $299.73 to $300.70).

Referenced by the price of 1 transaction in Table I.

F8

Open market sales reported on this line occurred at a weighted average price of $300.89 (range $300.78 to $301.03).

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)